9 Meters Biopharma, Inc. MNTRQ

Market cap: $1.0M
P/E: 0.0×

Follow MNTRQ

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions

in millions of $

	Nov 25			Feb 26			May 26			Aug 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 10.64%

Capital & Financial Ratios

Market Cap 1.04

Revenue 4.07

Net Income (46.28)

Free Cash Flow (37.24)

Net Debt (2.45)

Current Ratio 0.59

Debt/Equity (0.82)

P/E ratio 0.00

P/S ratio 0.07

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next 5Y EPS Growth —

in millions of $

Dividends

Payout Ratio 0.00

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

	2020	2021	2022	Q'23
Cash	38	47	13	8
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	0	3	17	2
	39	50	33	9

	2020	2021	2022	Q'23
Payables	1	2	5	4
ST’ Debt	0	0	20	5
Other	0	6	2	0
	7	8	31	16

in millions of $

Compound Annual Growth

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—

in millions of $ · fiscal quarters ending in the months shown

Operating Cash Flow

	Mar	Jun	Sep	Dec	Year
’26	(10)	—	—	—	—
’22	(10)	(8)	(10)	(10)	(37)
’21	(6)	(7)	(8)	(8)	(29)
’20	(3)	(6)	(4)	(6)	(19)
’19	(4)	(7)	(4)	(3)	(18)
’18	(7)	(2)	(3)	(2)	(15)
’17	(1)	(1)	(1)	(2)	(5)

in millions of $ · fiscal quarters ending in the months shown

Free Cash Flow

	Mar	Jun	Sep	Dec	Year
’26	(10)	—	—	—	—
’22	(10)	(8)	(10)	(10)	(37)
’21	(6)	(7)	(8)	(8)	(29)
’20	(3)	(6)	(4)	(6)	(19)
’19	(4)	(7)	(4)	(3)	(18)
’18	(7)	(2)	(3)	(2)	(15)
’17	(1)	(1)	(1)	(2)	(5)

in millions of $ · fiscal quarters ending in the months shown

EPS

	Mar	Jun	Sep	Dec	Year
’26	(1.02)	—	—	—	—
’22	(0.80)	(0.80)	(0.72)	(0.92)	(3.38)
’21	(0.60)	(0.60)	(1.00)	(0.80)	(3.00)
’20	(1.80)	(11.40)	(1.20)	2.64	(11.60)
’19	(3.20)	(2.60)	(5.20)	(5.20)	(16.23)
’18	(15.20)	(3.20)	(0.60)	(2.20)	(19.60)
’17	(6.71)	(4.69)	(1.55)	(6.57)	(19.53)

fiscal quarters ending in the months shown

2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
—	—	—	—	—	—	—	—	—	—	Analyst estimates 2023–2025 Powerpack	Low Price
—	—	—	—	—	—	—	—	—	—		High Price
—	—	—	15	5	8	8	12	21	10		Employees
—	—	—	0	0	0	0	0	0	0		Revenue/Emp
—	—	—	4	—	—	—	—	—	—		Revenue
—	—	—	18.11%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%		Gross Margin
—	—	—	(6)	(12)	(24)	(27)	(61)	(37)	(44)		EBT
—	—	—	(152.79%)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%		EBT Margin
—	—	—	(6)	(12)	(24)	(27)	(61)	(37)	(44)		Net Income
—	—	—	2	0	3	1	2	0	2		Depreciation
—	—	—	147.28	0.00	0.00	0.00	0.00	0.00	0.00		Revenue/Sh
—	—	—	(224.00)	(19.53)	(19.60)	(15.60)	(11.60)	(3.00)	(3.38)		Earnings/Sh
—	—	—	(305.33)	(8.57)	(12.25)	(10.78)	(3.67)	(2.43)	(2.87)		Cash Flow/Sh
—	—	—	0.00	(0.07)	(0.01)	(0.01)	0.00	0.00	0.00		Capex/Sh
—	—	—	(305.33)	(8.64)	(12.26)	(10.79)	(3.68)	(2.43)	(2.87)		Free CF/Sh
—	—	—	90.14	(20.48)	(2.96)	(5.77)	6.09	3.42	0.19		Book Value/Sh
—	—	—	0	1	1	2	5	12	13		Shares
—	—	—	0.00	—	—	—	—	—	—		PE Ratio
—	—	—	2.38	—	—	—	—	—	—		PS Ratio
—	—	—	3.88	—	—	—	—	—	—		PB Ratio
—	—	—	2.10	—	—	—	—	—	—		EV/Sales
—	—	—	(1.01)	—	—	—	—	—	—		EV/FCF
—	—	—	(8)	(5)	(15)	(18)	(19)	(29)	(37)		Op' Cash Flow
—	—	—	—	0	0	0	0	0	0		Capex
—	—	—	(8)	(5)	(15)	(18)	(19)	(29)	(37)		FCF
—	—	—	0	(12)	(4)	(10)	32	42	2		Working Cap'
—	—	—	0	9	5	3	0	0	20		Total Debt
—	—	—	(1)	8	(1)	(1)	(38)	(47)	7		Net Debt
—	—	—	2	(12)	(4)	(10)	32	42	2		Sh' Equity
—	—	—	(111.13%)	(319.61%)	(666.30%)	(460.37%)	(276.67%)	(82.34%)	(105.05%)		ROA
—	—	—	(346.17%)	0.00%	0.00%	0.00%	0.00%	0.00%	(278.41%)		ROIC
—	—	—	387.59%	239.63%	305.20%	407.57%	(545.95%)	(99.75%)	(198.92%)		ROE

predictions in italic, sparklines do not include predictions

All 10 years →

Fiscal years to Dec 2016 · latest quarter Dec 2016

Company	Market cap	P/E	Compare
BPTH Bio-Path Holdings, Inc.	$1.1M	0.0×	Compare
ZVSA ZyVersa Therapeutics, Inc.	$970.0K	0.0×	Compare
CYTOF Altamira Therapeutics Ltd.	$1.1M	0.0×	Compare
SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR	$1.2M	0.0×	Compare

Company	Market cap	P/E	Compare
LYRA Lyra Therapeutics, Inc.	$870.0K	0.0×	Compare
PTIX Atrinsic Inc.	$1.3M	0.3×	Compare
BTTX Better Therapeutics, Inc.	$850.0K	0.0×	Compare
BBLG Bone Biologics Corp.	$1.4M	0.0×	Compare

All 616 Biotechnology stocks →